The pro-oncogenic activities of HDACs, along with structural and activity features that render HDACs viable therapeutic targets, provide sufficient rationale to develop and utilize HDAC inhibition for the clinical management of human cancers, including breast cancer [135]. The gene discussed is HDAC9; the disease is cancer.